TICKERNERD
Menu
PRMEPRMEHealthcare · Biotechnology

PRME Stock Forecast: Prime Medicine, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$2.81
−3.77% on the day

The 13 Wall Street analysts covering Prime Medicine, Inc. hold a median 12-month price target of $7.46 — +165.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$527.4M
Ticker Nerd rank
34 / 100
Median analyst target
$7.46
Analysts covering
13
Total return, dividends reinvested
1W
−6.6%
1M
−27.4%
YTD
−19.0%
1Y
−30.4%
From 52W high
−57.9%
From 52W low
+4.1%
$2.70
$6.67
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PRME stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Prime Medicine, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
34 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
67
Growth
62
Momentum
57
Size
52
Issuance
51
Quality
35
Revisions
32
Value
30
Volatility
15

Accruals (67): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (15): The share price moves around a lot.

The rank is the raw material. Whether the rules would actually own Prime Medicine, Inc. — and when they’d sell — is the membership.

Wall Street

PRME stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PRME, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26PRMEHigh $11.00Median $7.46Low $4.25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says13 analysts
10 Buy3 Hold0 Sell
Low $4.25Median $7.46High $11.00

The green dot is the last close — the median target sits +165.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 June 2026HC Wainwright & Co.UpgradeBuy$8.00
12 Mar 2026OppenheimerInitiatesOutperform—
23 Dec 2025LifeSci CapitalInitiatesOutperform—
11 Nov 2025CitigroupMaintainsNeutral—
10 Nov 2025Chardan CapitalMaintainsBuy—
12 Aug 2025CitigroupMaintainsNeutral—
8 Aug 2025Chardan CapitalMaintainsBuy—
27 May 2025CitigroupDowngradeNeutral—
20 May 2025HC Wainwright & Co.DowngradeNeutral—
20 May 2025JMP SecuritiesMaintainsMarket Outperform—
20 May 2025JP MorganDowngradeNeutral—
19 May 2025Chardan CapitalMaintainsBuy—
20 Mar 2025Chardan CapitalMaintainsBuy—
19 Mar 2025HC Wainwright & Co.ReiteratesBuy—
4 Mar 2025Citizens Capital MarketsReiteratesMarket Outperform—
3 Mar 2025Chardan CapitalMaintainsBuy—
3 Mar 2025HC Wainwright & Co.ReiteratesBuy—
10 Dec 2024JMP SecuritiesInitiatesMarket Outperform—
3 Dec 2024GuggenheimReiteratesBuy—
25 Oct 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

PRME analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Prime Medicine, Inc. (PRME) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.2×

Cheaper than 85% of US stocks

Price / sales
130.7×

Cheaper than 3% of US stocks

Price / book
6.9×

Cheaper than 15% of US stocks

EV / EBITDA
−2.5×

Cheaper than 74% of US stocks

Growth & margins
Revenue growth (YoY)
−41.1%

Higher than 6% of US stocks

Earnings growth (YoY)
−41.1%

Higher than 12% of US stocks

Gross margin
—
Operating margin
−5917.5%

Higher than 3% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−216.1%

Higher than 6% of US stocks

Return on assets
−41.5%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PRME vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PRMEPrime Medicine, Inc.$527.4M
34
FDMT4D Molecular Therapeutics, Inc.$519.3M
65
TECXTectonic Therapeutic, Inc.$524.6M
50
ARVNArvinas, Inc.$515.7M
56
ZURAZura Bio Ltd.$515.2M
33
DNAGinkgo Bioworks Holdings, Inc.$528.5M
54
VSTMVerastem, Inc.$509.4M
32
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PRME appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest PRME news & analysis

Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Zacks Investment Research · 30 July 2026negative

Zacks Investment Research reported that Prime Medicine, Inc. (PRME) lacks the necessary combination of factors for a likely earnings beat in its upcoming Q2 report. The article advises investors to prepare with key expectations ahead of the release.

Why it matters — PRME watchers would monitor this ahead of the Q2 earnings release because a potential negative earnings report could impact investor sentiment and the stock's near-term performance.

FAQ

Frequently asked questions about PRME stock

What is the PRME stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Prime Medicine, Inc. have a median 12-month price target of $7.46, with estimates ranging from $4.25 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PRME stock a buy right now?

Of the 13 analysts covering Prime Medicine, Inc., 10 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Prime Medicine, Inc. 34 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PRME?

As at 1 Aug 2026, Prime Medicine, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (67 of 100).

Will PRME stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +165.5% from the last close, and Ticker Nerd's factor model ranks Prime Medicine, Inc. 34 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PRME stock forecast for 2030?

No analyst covering Prime Medicine, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRME are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.25 to $11 over the next 12 months.

How has PRME stock performed over the past year?

Prime Medicine, Inc. returned -30.4% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Prime Medicine, Inc. do?

Prime Medicine Inc. is a clinical-stage biotechnology company specializing in genetic therapies based on its proprietary Prime Editing platform.

What is the latest news on PRME?

The most recent item we track (Zacks Investment Research, 30 July 2026): "Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release". Zacks Investment Research reported that Prime Medicine, Inc. (PRME) lacks the necessary combination of factors for a likely earnings beat in its upcoming Q2 report. The article advises investors to prepare with key expectations ahead of the release.

Company

About Prime Medicine, Inc.

Prime Medicine Inc. is a clinical-stage biotechnology company specializing in genetic therapies based on its proprietary Prime Editing platform. The company focuses on developing one-time genetic treatments that precisely modify DNA to address the underlying causes of disease. Prime Medicine’s Prime Editing technology combines engineered Prime Editor proteins with specialized guide RNAs to “search and replace” targeted DNA sequences, enabling corrections, insertions, or deletions without creating double-stranded breaks in the genome. Today, Prime Medicine is advancing a diversified pipeline of investigational therapies across hematology, immunology and oncology, as well as liver and lung indications, with an emphasis on rare and severe genetic disorders and diseases with clearly defined biology. Operating as a single, research-driven segment, the company generates value through discovery, preclinical and clinical development of prime editing-based candidates, and collaborations with other biopharmaceutical firms in areas such as cell therapies and shielded-cell immunotherapies. Founded in 2019 and headquartered in Cambridge, Massachusetts, Prime Medicine occupies a prominent position in the emerging gene editing and genetic medicines sector.

CEO Dr. Allan Reine M.D. · 146 employees · United States · https://primemedicine.com